Outcomes of Related Donor HLA-Identical or HLA-Haploidentical Allogeneic Blood or Marrow Transplantation for Peripheral T Cell Lymphoma

ArticleinBiology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation 19(4) · January 2013with36 Reads
DOI: 10.1016/j.bbmt.2013.01.006 · Source: PubMed
BACKGROUND: The role of allogeneic blood or marrow transplantation (alloBMT) for peripheral T-cell lymphoma (PTCL) remains to be defined. There is growing interest in reduced-intensity conditioning (RIC) regimens and/or utilization of HLA-haploidentical (haplo) grafts given concerns about treatment-associated toxicities and donor availability. METHODS: We reviewed the outcomes of 44 consecutive, related donor alloBMTs for PTCL performed at Johns Hopkins Hospital from 1994-2011, including 18 RIC/haplo alloBMTs. RESULTS: Patients receiving RIC (n=24) were older with median age of 59 years (range 24-70) than patients receiving myeloablative conditioning (MAC, n=20) with median age of 46 years (range 18-64), p=0.01. The median age at RIC/haplo alloBMT was 60 years. The estimated 2-year progression-free survival (PFS) was 40% (95% confidence interval (CI) 26-55%) and overall survival (OS) was 43% (95% CI 28-59%). In older patients (> 60, n=14), the estimated 2-year PFS and OS were 38% (CI 18-79%) and 45% (CI 24-86%). On unadjusted analysis, there was a tendency towards superior outcomes for alloBMT in first remission versus beyond first remission, with an estimated 2-year PFS of 53% (95% CI 33-77%) versus 29% (95% CI 9-45%), p=0.08. On competing risk analysis, the 1-year cumulative incidence of relapse was 38% for MAC/HLA-identical alloBMTs and 34% for RIC/haplo alloBMTs. Estimated 1-year non-relapse mortality was 10% for MAC and 8% for RIC (11% for RIC/haplo alloBMT). On unadjusted landmark analysis, patients with acute grade II-IV or chronic GVHD had a 17% probability of relapse (95% CI 0-39%), compared to 66% (95% CI 48-84%) in patients without GVHD, p=0.04. CONCLUSIONS: Utilization of RIC and alternative donors expands treatment options in PTCL to those who are older and unable to tolerate high-dose conditioning, with outcomes comparable to approaches using myeloablative regimens and HLA-matched donors. AlloBMT may be appropriate in first remission in select high-risk cases.
    • "Although statistical power is limited, these data suggests that survival for patients with AML after haploidentical transplantation with PT-CY is comparable with matched unrelated donor transplantation. Other studies have shown superimposable outcome of transplants from HAPLO compared to unrelated and also sibling donors [13,[21][22][23][24][25][26]. The lack of prospective randomized trials makes it difficult to prioritize a given donor type; however, HAPLO transplants offer several advantages, including the high probability of finding a donor, a short time to transplant, low cost, and comparable outcome. "
    [Show abstract] [Hide abstract] ABSTRACT: The use of high dose posttransplant cyclophosphamide (PT-CY) introduced by the Baltimore group approximately 10 years ago has been rapidly adopted worldwide and is becoming a standard for patients undergoing unmanipulated haploidentical (HAPLO) transplants. PT-CY has been used following nonmyeloablative as well as myeloablative conditioning regimens, for bone marrow or peripheral blood grafts, for patients with malignant and nonmalignant disorders. Retrospective comparisons of HAPLO grafts with conventional sibling and unrelated donor grafts have been published and suggest comparable outcome. The current questions to be answered include the use of PT-CY for sibling and unrelated donors transplant, possibly in the context of prospective randomized trial.
    Full-text · Article · Apr 2016
  • [Show abstract] [Hide abstract] ABSTRACT: T-cell non-Hodgkin lymphomas (NHL) are a heterogeneous group of malignancies that represent 10-15% of all NHL. The prognosis of relapsed T-cell NHL is poor, especially for those relapsing after an autologous (auto-) or allogeneic (allo-) hematopoietic cell transplantation (HCT). Disease relapse post auto-HCT is best managed on a clinical trial. In the absence of a investigational protocol, the choice of salvage therapies should take into account patient performance status, eligibility for an allo-HCT, and surface CD30 expression. CD30-directed therapies or aggressive salvage regimens can be used as a bridge to allo-HCT in medically fit patients. In the elderly or more infirm patients single-agent therapies could be offered, aiming at palliation. Similarly, relapse after an allo-HCT is not uncommon and is a real challenge. Reduction in ongoing immune suppression or donor lymphocyte infusion are often considered in this setting to augment graft-versus-lymphoma (GVL) effects and can occasionally provide durable disease control. Clinical trials designed to investigate novel therapeutic agents with immunomodulatory properties to augment GVL effects (e.g. HDAC inhibitors, proteasome inhibitor, lenalidomide) or targeted therapies (e.g. aurora A kinase inhibitors, ALK inhibitors) are sorely needed to improve the dismal outcomes of T-cell NHL relapsing after an allo-HCT.
    Article · Nov 2013
  • [Show abstract] [Hide abstract] ABSTRACT: Peripheral T-cell lymphomas (PTCL) are a diverse group of lymphoproliferative disorders, which share a common denominator of overall poor prognosis, with few exceptions. In this article, the authors review current standard of care approaches for the treatment of PTCLs, the role of stem-cell/bone marrow transplantation, and current developments in novel targeted therapies.
    Full-text · Article · May 2013
Show more